KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...

TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00.

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma ...

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has announced the completion of enrollment for its KONFIDENT-KID clinical trial, which evaluates sebetralstat ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary ...

Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Matteis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma ...